Ligand ID: CYZ


Drugbank ID:
DB00606
(Cyclothiazide)


Indication:
Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Get human targets for CYZ in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'CYZ' AND SARS-RELATED PROTEINS ONLY

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 10
MET A  67
SER A  66
LEU A  22
ILE E 112
SER A  62
1.67A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 11
ILE E 112
SER A  62
MET A  67
SER A  66
LEU A  22
1.69A11.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 10
MET A  67
SER A  66
LEU A  22
ILE E 112
SER A  62
1.71A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 10
MET A  67
SER A  66
LEU A  22
ILE E 112
SER A  62
1.69A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 10
MET A  67
SER A  66
LEU A  22
ILE E 112
SER A  62
1.69A6.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 11
ILE E 112
SER A  62
MET A  67
SER A  66
LEU A  22
1.69A11.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		5 / 11
SER A 128
LEU A 503
SER A 507
LEU A 176
SER A 124
1.70A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		5 / 12
SER A 128
LEU A 503
SER A 507
LEU A 176
SER A 124
1.78A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_B_CYZB265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.58A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_B_CYZB265_1
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 9
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.59A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO H  74
MET H  57
SER H  72
SER H  54
LEU H  55
1.56A16.81
None
None
None
None
D10  H1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO F  74
MET F  57
SER F  72
SER F  54
LEU F  55
1.55A16.37
None
None
None
None
D10  F1099 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 11
PRO H  74
MET H  57
SER H  72
SER H  54
LEU H  55
1.56A16.81
None
None
None
None
D10  H1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2cme -
(-)		5 / 12
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.57A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 11
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.56A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 11
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.57A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		2cme -
(-)		5 / 9
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.58A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 9
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.58A17.19
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.55A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 12
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.55A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_B_CYZB265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO F  74
MET F  57
SER F  72
SER F  54
LEU F  55
1.57A16.81
None
None
None
None
D10  F1099 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.55A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.57A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 11
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.58A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_B_CYZB265_1
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.57A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 12
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.56A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 9
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.57A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 12
PRO H  74
MET H  57
SER H  72
SER H  54
LEU H  55
1.55A16.81
None
None
None
None
D10  H1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		2dd8 IGG LIGHT CHAIN
(Homo
sapiens)		4 / 5
ILE L  28
SER L  32
LYS L  31
GLY L  29
1.53A21.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO S 469
PRO S 459
LEU S 443
LEU S 478
ASP S 480
1.71A11.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO S 469
PRO S 459
LEU S 443
LEU S 478
ASP S 480
1.70A11.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2fyg REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 10
LEU A  14
ASP A  22
ILE A  38
PRO A  37
GLY A 109
1.70A8.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 11
ILE L  38
SER L  72
PRO L 107
LEU L  75
LEU L  92
1.48A9.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 11
ILE L  38
SER L  72
PRO L 107
LEU L  75
LEU L  92
1.48A9.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 9
GLY R  50
MET R  44
SER R  67
LEU K  45
LEU R  45
1.65A9.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 12
PRO I 107
LEU I  75
LEU I  92
ILE I  38
SER I  72
1.51A18.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 11
PRO I 107
LEU I  75
LEU I  92
ILE I  38
SER I  72
1.42A18.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 10
LEU W  14
ASP W  22
ILE W  38
PRO W  37
GLY W 109
1.65A9.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
SER A  67
LEU A  93
LEU A 111
LYS A   1
ILE A  91
1.39A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		5 / 12
LEU A  96
LEU A 112
LYS A   1
SER A  63
LYS A  61
1.44A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
LEU A 443
LEU A 478
ASP A 480
PRO A 469
SER B 163
1.75A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 9
PRO A 459
ASP A 480
PRO A 469
SER B 163
GLY B 198
1.69A11.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 199
PRO A 459
LEU A 443
LEU A 478
ASP A 480
1.37A13.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
LEU A 443
LEU A 478
ASP A 480
PRO A 469
SER B 163
1.74A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
PRO A 459
PRO A 469
SER B 199
SER B 163
GLY B 198
1.32A11.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		6 / 9
PRO A 469
SER B 163
GLY B 198
LEU A 443
LEU A 478
ASP A 480
1.75A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
LEU A 443
LEU A 478
ASP A 480
PRO A 469
SER B 163
1.75A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		6 / 10
LEU A 443
LEU A 478
ASP A 480
PRO A 469
SER B 163
GLY B 198
1.76A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		6 / 11
PRO A 469
SER B 163
PRO A 459
LEU A 443
LEU A 478
ASP A 480
1.69A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_C_CYZC1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 9
PRO A 469
SER B 199
SER B 163
GLY B 198
PRO A 459
1.31A11.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 199
PRO A 459
LEU A 443
LEU A 478
ASP A 480
1.37A13.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		6 / 11
PRO A 469
SER B 163
PRO A 459
LEU A 443
LEU A 478
ASP A 480
1.69A11.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE B 107
SER B 114
PRO B 111
LEU B 119
SER B 118
1.71A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
PRO C 111
LEU C 119
SER C 118
ILE C 107
SER C 114
1.73A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 9
SER B 161
LEU B 122
ASP B 272
LYS B  89
ILE B 143
1.76A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
LEU D  75
LEU D 142
ASP D 124
ILE D  71
PRO D 157
1.77A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
LEU D  75
LEU D 142
ASP D 124
ILE D  71
PRO D 157
1.75A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 9
PRO C 111
LEU C 119
SER C 118
ILE C 107
SER C 114
1.73A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE B 107
SER B 114
PRO B 111
LEU B 119
SER B 118
1.71A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
PRO C 111
LEU C 119
SER C 118
ILE C 107
SER C 114
1.73A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
LEU D  75
LEU D 142
ASP D 124
ILE D  71
PRO D 157
1.75A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
PRO A 111
LEU A 119
SER A 118
ILE A 107
SER A 114
1.56A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE C 107
SER C 114
PRO C 111
LEU C 119
SER C 118
1.56A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE C 107
SER C 114
PRO C 111
LEU C 119
SER C 118
1.56A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
PRO A 111
LEU A 119
SER A 118
ILE A 107
SER A 114
1.56A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
PRO E 111
LEU E 119
SER E 117
ILE E 107
SER E 114
1.77A23.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 9
PRO A 111
LEU A 119
SER A 118
ILE A 107
SER A 114
1.59A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 9
PRO A 111
LEU A 119
SER A 118
ILE A 107
SER A 114
1.56A16.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr)		5 / 10
LEU A 161
LEU A 275
ILE A 167
SER A 188
GLY A 208
1.27A13.98
None
None
None
MG  A1296 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
LEU A 161
LEU A 275
ILE A 167
SER A 188
GLY A 208
1.26A14.50
None
None
None
MG  A1299 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
SER L 116
ILE H 212
PRO H 126
SER H 182
GLY H 141
1.64A11.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3bgf F26G19 FAB
(Mus
musculus)		5 / 9
SER L 116
ILE H 212
PRO H 126
SER H 182
GLY H 141
1.64A11.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
MET C 175
SER C 174
LEU B 179
SER B 180
SER B 182
1.54A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		5 / 11
MET L 175
SER L 174
LEU H 179
SER H 180
SER H 182
1.49A20.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
MET C 175
SER C 174
LEU B 154
SER B 181
GLY B 164
1.70A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
MET C 175
SER C 174
LEU B 179
SER B 180
SER B 182
1.53A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		5 / 11
PRO H 169
MET L 175
LEU H 179
SER H 180
SER H 182
1.75A21.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
PRO H 126
SER L 116
ILE H 212
SER H 182
GLY H 141
1.71A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
MET C 175
SER C 174
LEU B 179
SER B 180
SER B 182
1.53A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
MET C 175
SER C 174
LEU B 154
SER B 181
GLY B 164
1.70A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
PRO H 126
SER L 116
ILE H 212
SER H 182
GLY H 141
1.72A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
PRO B 169
MET C 175
LEU B 179
SER B 180
SER B 182
1.66A21.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 11
SER B 182
MET C 175
SER C 174
LEU B 179
SER B 180
1.53A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3bgf F26G19 FAB
(Mus
musculus)		5 / 9
PRO H 126
SER L 116
ILE H 212
SER H 182
GLY H 141
1.76A12.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3bgf F26G19 FAB
(Mus
musculus)		5 / 10
PRO H 126
SER L 116
ILE H 212
SER H 182
GLY H 141
1.76A12.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		5 / 12
MET C 175
SER C 174
LEU B 179
SER B 180
SER B 182
1.40A20.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3bgf F26G19 FAB
(Mus
musculus)		5 / 11
SER B 182
MET C 175
SER C 174
LEU B 179
SER B 180
1.53A12.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO E 469
PRO E 459
LEU E 443
LEU E 478
ASP E 480
1.58A10.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO E 469
PRO E 459
LEU E 443
LEU E 478
ASP E 480
1.57A10.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
ASP A 615
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.52A19.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 9
ASP A 615
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.53A19.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.77A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.68A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO F 469
PRO F 459
LEU F 443
LEU F 478
ASP F 480
1.55A10.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO F 469
PRO F 459
LEU F 443
LEU F 478
ASP F 480
1.56A10.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 5
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.33A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 11
ILE F   7
SER D  71
SER D   9
LEU F   9
LEU D  78
1.67A0.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 10
SER D   9
LEU F   9
LEU D  78
ILE F   7
SER D  71
1.69A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 10
SER D   9
LEU F   9
LEU D  78
ILE F   7
SER D  71
1.68A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 11
ILE F   7
SER D  71
SER D   9
LEU F   9
LEU D  78
1.67A0.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3i6l HLA, A-24
NUCLEOPROTEIN
PEPTIDE
(Homo
sapiens;
SARSr-CoV)		5 / 10
SER D   9
LEU F   9
LEU D  78
ILE F   7
SER D  71
1.68A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
LEU A 242
LEU A 262
ASP A 263
ILE A 249
GLY A 251
1.57A14.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
LEU A 161
LEU A 275
ILE A 167
SER A 188
GLY A 208
1.27A16.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3sci ACE2
(Homo
sapiens)		5 / 10
PRO A 612
ILE A 256
PRO A 263
SER A 607
GLY A 260
1.66A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3sci ACE2
(Homo
sapiens)		5 / 11
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.68A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		3sci ACE2
(Homo
sapiens)		5 / 9
PRO A 612
ILE A 256
PRO A 263
SER A 607
GLY A 260
1.65A20.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3sci ACE2
(Homo
sapiens)		5 / 12
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.77A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 5
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.42A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.79A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.58A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LYS F 324
SER F 386
LEU F 421
ILE F 345
LYS F 382
1.71A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LYS F 324
SER F 386
LEU F 421
ILE F 345
LYS F 382
1.68A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 124
SER B 128
LEU B 503
SER B 507
LEU B 176
1.79A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO E 469
PRO E 459
LEU E 443
LEU E 478
ASP E 480
1.59A10.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.69A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.80A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.74A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO E 469
PRO E 459
LEU E 443
LEU E 478
ASP E 480
1.60A10.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
SER B 124
SER B 128
LEU B 503
SER B 507
LEU B 176
1.79A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		4m0w REPLICASE
POLYPROTEIN 1A
UBIQUITIN
(Bos
taurus;
SARSr-CoV)		5 / 10
LEU B   8
LEU B  73
ASP A 165
SER A 246
GLY A 210
1.62A6.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		4m0w REPLICASE
POLYPROTEIN 1A
UBIQUITIN
(Bos
taurus;
SARSr-CoV)		5 / 9
SER A 246
GLY A 210
LEU B   8
LEU B  73
ASP A 165
1.62A16.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		4mm3 PAPAIN-LIKE
PROTEINASE
UBIQUITIN
(Homo
sapiens;
SARSr-CoV)		5 / 9
SER B 246
GLY B 210
LEU A   8
LEU A  73
ASP B 165
1.63A15.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
LEU D 170
LEU D 117
ILE D  87
SER D 271
GLY D  88
1.58A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
LEU D 170
LEU D 117
ILE D  87
SER D 271
GLY D  88
1.56A19.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
LEU A 170
LEU A 117
ILE A  87
SER A 271
GLY A  88
1.63A19.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ILE B 584
PRO B 586
SER B 659
GLY B 298
1.28A11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
ILE A 296
SER A 299
PRO A 145
LEU A 172
SER A 224
1.75A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 9
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.75A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.69A20.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
ILE A 296
SER A 299
PRO A 145
LEU A 172
SER A 224
1.75A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 10
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.72A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 10
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.73A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.75A20.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x4r S PROTEIN
(MERS-CoV)		5 / 9
PRO A  97
LEU A 100
SER A 299
LYS A 308
ILE A  31
1.74A15.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 11
SER B 582
SER C 750
LEU C 846
LEU C 843
ASP B 600
1.74A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER C 750
LEU C 846
LEU C 843
ASP B 600
SER B 582
1.75A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 11
SER B 582
SER C 750
LEU C 846
LEU C 843
ASP B 600
1.73A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER C 750
LEU C 846
LEU C 843
ASP B 600
SER B 582
1.75A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
LEU B1031
LYS B1010
ILE B 891
SER B1019
LYS B1020
1.79A12.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 9
PRO B 394
SER B 498
SER B 532
LEU B 567
LEU B 495
1.75A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 10
SER C 965
LEU C 964
ILE B 768
PRO B 767
SER C 954
1.73A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 10
SER C 965
LEU C 964
ILE B 768
PRO B 767
SER C 954
1.73A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 11
ILE B 768
PRO B 767
SER C 954
SER C 965
LEU C 964
1.74A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 10
SER C 965
LEU C 964
ILE B 768
PRO B 767
SER C 954
1.68A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x59 S PROTEIN
(MERS-CoV)		5 / 11
ILE B 768
PRO B 767
SER C 954
SER C 965
LEU C 964
1.73A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER A 750
LEU A 846
LEU A 843
ASP C 600
SER C 582
1.74A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER B 750
ASP A 600
ILE A 650
SER A 582
GLY A 298
1.39A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER B 750
ASP A 600
ILE A 650
SER A 582
GLY A 298
1.35A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 9
SER B 750
ASP A 600
ILE A 650
SER A 582
GLY A 298
1.35A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 11
SER C 985
LEU C 959
LEU C 948
ILE C 975
SER C 950
1.64A12.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 5
ILE A 650
PRO A 651
SER A 582
GLY A 298
1.74A12.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
SER B 750
ASP A 600
ILE A 650
SER A 582
GLY A 298
1.38A21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5c S PROTEIN
(MERS-CoV)		5 / 10
LEU A 673
SER A 660
ASP B 805
ILE A 662
GLY A 359
1.66A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5c S PROTEIN
(MERS-CoV)		5 / 10
LEU A 673
SER A 660
ASP B 805
ILE A 662
GLY A 359
1.66A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		5x5f S PROTEIN
(MERS-CoV)		5 / 9
MET C 696
SER C 695
LEU C 347
SER C 345
ASP C 338
1.76A11.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5x5f S PROTEIN
(MERS-CoV)		5 / 10
SER C 532
LEU C 567
LEU C 495
PRO C 394
SER C 498
1.75A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		5x5f S PROTEIN
(MERS-CoV)		5 / 12
LYS A1102
SER A 852
LEU A1098
ILE A 795
SER A 845
1.65A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		5x5f S PROTEIN
(MERS-CoV)		5 / 11
LYS A1102
SER A 852
LEU A1098
ILE A 795
SER A 845
1.72A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
PRO A 469
PRO A 459
LEU A 443
LEU A 478
ASP A 480
1.80A22.63
PRO  A 469 ( 1.1A)
PRO  A 459 ( 1.1A)
LEU  A 443 ( 0.5A)
LEU  A 478 ( 0.6A)
ASP  A 480 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 12
LEU C 920
SER C 919
LEU b  25
LYS b  23
ILE c  29
1.71A14.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 10
LEU C 920
SER C 919
LEU b  25
LYS b  23
ILE c  29
1.77A6.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 10
LEU C 920
SER C 919
LEU b  25
LYS b  23
ILE c  29
1.76A6.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 11
ILE c  29
LEU C 920
SER C 919
LEU b  25
LYS b  23
1.77A3.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 11
ILE c  29
LEU C 920
SER C 919
LEU b  25
LYS b  23
1.77A3.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER A 541
LEU A 532
LEU A 538
LYS A 521
SER A 568
1.74A11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
SER A 370
LEU C 978
SER C 956
ILE C 975
SER C 964
1.73A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 5
ILE C1112
PRO C1061
SER C1083
GLY C1113
1.70A11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
SER A 370
LEU C 978
SER C 956
ILE C 975
SER C 964
1.72A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 574
LEU A 948
SER B 556
ASP B 554
GLY A 839
1.37A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER A 541
LEU A 532
LEU A 538
LYS A 521
SER A 568
1.50A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 574
LEU A 948
SER B 556
ASP B 554
GLY A 839
1.36A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER B 568
SER B 541
LEU B 532
LEU B 538
LYS B 521
1.52A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_B_CYZB265_1
(GLUTAMATE RECEPTOR 2)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
MET A 709
SER A1003
LEU A 930
ASP A 932
LYS A 929
1.62A11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 541
LEU B 532
LEU B 538
LYS B 521
SER B 568
1.52A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
MET A 709
SER A1003
LEU A 930
ASP A 932
LYS A 929
1.68A11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 541
LEU B 532
LEU B 538
LYS B 521
SER B 568
1.52A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER B 568
SER B 541
LEU B 532
LEU B 538
LYS B 521
1.52A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
SER B 568
SER B 541
LEU B 532
LEU B 538
LYS B 521
1.53A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
SER B 541
LEU B 532
LEU B 538
LYS B 521
SER B 568
1.52A22.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER B 919
LEU B1045
LEU B 804
LYS B 807
ILE B 704
1.77A11.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
PRO B 651
LEU B 597
SER B 582
ILE B 584
GLY B 298
1.74A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
ILE B 319
PRO B 317
SER B 516
LEU B 322
LEU B 374
1.64A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
PRO B 651
LEU B 597
SER B 582
ILE B 584
GLY B 298
1.74A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
ILE B 319
PRO B 317
SER B 516
LEU B 322
LEU B 374
1.64A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
SER A 919
LEU A1045
LEU A 804
LYS A 807
ILE A 704
1.63A11.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 919
LEU C1045
LEU C 804
LYS C 807
ILE C 704
1.72A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
LEU A1031
LYS A1010
ILE A 891
SER A1019
LYS A1020
1.64A11.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 919
LEU C1045
LEU C 804
LYS C 807
ILE C 704
1.69A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 919
LEU C1045
LEU C 804
LYS C 807
ILE C 704
1.69A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6cs2 ACE2
(Homo
sapiens)		5 / 11
SER D 128
LEU D 503
SER D 507
LEU D 176
SER D 124
1.74A19.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 9
SER C 950
GLY C 953
SER C 985
LEU C 959
LEU C 948
1.36A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER C 985
LEU C 959
LEU C 948
SER C 950
GLY C 953
1.36A22.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6jyt HELICASE
(SARSr-CoV)		5 / 10
PRO B 284
LEU B 438
ASP B 458
ILE B 399
GLY B 400
1.35A20.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		6jyt HELICASE
(SARSr-CoV)		5 / 10
PRO B 284
ASP B 458
ILE B 399
SER B 377
GLY B 400
1.49A20.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6jyt HELICASE
(SARSr-CoV)		5 / 10
PRO B 284
LEU B 438
ASP B 458
ILE B 399
GLY B 400
1.35A20.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6lzg ACE2
(Homo
sapiens)		4 / 5
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.27A19.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6m0j ACE2
(Homo
sapiens)		4 / 5
ILE A 259
PRO A 258
SER A 611
GLY A 260
1.26A19.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m17 ACE2
(Homo
sapiens)		5 / 10
LEU B 410
LEU B 370
ASP B 367
ILE B 407
GLY B 405
1.70A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6m18 ACE2
(Homo
sapiens)		4 / 5
ILE D 259
PRO D 258
SER D 611
GLY D 260
1.35A15.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
LEU C 242
LEU C 244
LYS C 409
ILE C 251
GLY C 250
1.19A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6m18 ACE2
(Homo
sapiens)		5 / 11
SER B 128
LEU B 503
SER B 507
LEU B 176
SER B 124
1.73A15.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
MET C 119
SER C 118
LEU C 111
LEU C 101
ASP C 445
1.78A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.42A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.38A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
MET C 119
SER C 118
LEU C 111
LEU C 101
ASP C 445
1.76A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.37A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.44A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.38A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 11
SER C 100
MET C 119
SER C 118
LEU C 111
ASP C 445
1.41A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.40A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 11
SER C 100
MET C 119
SER C 118
LEU C 111
ASP C 445
1.41A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d ACE2
(Homo
sapiens)		5 / 10
SER D 692
LEU D 148
ASP D 499
PRO D 135
SER D 170
1.72A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
MET C 119
SER C 118
LEU C 111
ASP C 445
SER C 100
1.42A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
SER A 100
MET A 119
SER A 118
LEU A 111
ASP A 445
1.42A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER C 919
LEU C1045
LEU C 804
LYS C 807
ILE C 704
1.75A12.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER C 919
LEU C1045
LEU C 804
LYS C 807
ILE C 704
1.65A12.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
PRO A 651
LEU A 597
SER A 582
ILE A 584
GLY A 298
1.74A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
PRO A 651
LEU A 597
SER A 582
ILE A 584
GLY A 298
1.74A21.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nur NSP12
(SARSr-CoV)		5 / 10
SER A 236
LEU A 240
ASP A 465
ILE A 233
PRO A 232
1.71A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nur NSP12
(SARSr-CoV)		5 / 11
ILE A 233
PRO A 232
SER A 236
LEU A 240
ASP A 465
1.72A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nus NSP12
(SARSr-CoV)		5 / 10
SER A 236
LEU A 240
ASP A 465
ILE A 233
PRO A 232
1.71A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nus NSP12
(SARSr-CoV)		5 / 11
ILE A 233
PRO A 232
SER A 236
LEU A 240
ASP A 465
1.71A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nus NSP12
(SARSr-CoV)		5 / 9
PRO A 232
GLY A 203
SER A 236
LEU A 207
ASP A 208
1.79A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6nus NSP12
(SARSr-CoV)		5 / 10
SER A 236
LEU A 240
ASP A 465
ILE A 233
PRO A 232
1.72A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_B_CYZB1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		6vw1 ACE2
(Homo
sapiens)		5 / 9
PRO B 612
ILE B 256
PRO B 263
SER B 607
GLY B 260
1.77A19.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5WEO_A_CYZA1302_1
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT
CHIMERA)		6vw1 ACE2
(Homo
sapiens)		5 / 10
PRO B 612
ILE B 256
PRO B 263
SER B 607
GLY B 260
1.78A19.88
None